多抗原特异性T细胞预防T细胞清除异基因干细胞移植后早期并发症的I/II期研究
部分病毒再激活后观察到靶抗原特异性T细胞扩增。
要点
- 多抗原特异性T细胞产品生成可行,中位产量5.2×10^6个细胞。
- 多数病毒再激活后观察到供者来源病毒靶抗原特异性T细胞扩增。
核心结论
- 多抗原特异性T细胞产品生成可行,回输耐受良好,且多数患者病毒再激活时伴随靶抗原特异性T细胞扩增。
研究设计与样本
- 利用MHC-I-Streptamers生成27份T细胞产品,中位细胞数5.2×10^6。
主要发现
- 随访期间无患者发生移植物抗宿主病。
- 5例患者疾病进展,未伴随TAA/MiHA特异性T细胞扩增。
- 8例患者发生CMV和/或EBV再激活,其中4例有临床意义需抗病毒治疗,2例进展为病毒病,最终均缓解。
- 2/4例EBV再激活和6/8例CMV再激活患者中,病毒载量之后观察到供者来源病毒靶抗原特异性T细胞扩增。
临床怎么用
- 该方法支持在T细胞清除异基因干细胞移植后通过供者来源多抗原特异性T细胞回输恢复特异性免疫。
- 回输后需监测病毒再激活及靶抗原特异性T细胞扩增情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prophylactic infusion of selected donor T cells can be an effective method to restore specific immunity after T-cell-depleted allogeneic stem cell transplantation (TCD-alloSCT). In this phase I/II study, we aimed to reduce the risk of viral complications and disease relapses by administrating donor-derived CD8pos T cells directed against cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus antigens, tumor-associated antigens (TAA) and minor histocompatibility antigens (MiHA). Twenty-seven of thirty-six screened HLA-A*02:01pos patients and their CMVpos and/or EBVpos donors were included. Using MHC-I-Streptamers, 27 T-cell products were generated containing a median of 5.2 × 106 cells. Twenty-four products were administered without infusion-related complications at a median of 58 days post alloSCT. No patients developed graft-versus-host disease during follow-up. Five patients showed disease progression without coinciding expansion of TAA/MiHA-specific T cells. Eight patients experienced CMV- and/or EBV-reactivations. Four of these reactivations were clinically relevant requiring antiviral treatment, of which two progressed to viral disease. All resolved ultimately. In 2/4 patients with EBV-reactivations and 6/8 patients with CMV-reactivations, viral loads were followed by the expansion of donor-derived virus target-antigen-specific T cells. In conclusion, generation of multi-antigen-specific T-cell products was feasible, infusions were well tolerated and expansion of target-antigen-specific T cells coinciding viral reactivations was illustrated in the majority of patients.
引用
- Roex MCJ, van Balen P, Germeroth L, et al. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study. Leukemia. 2019. PMID: 31624377. doi:10.1038/s41375-019-0600-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。